{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:22:49Z","timestamp":1764087769547,"version":"3.45.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Nucleus Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40487-025-00380-0","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T04:42:44Z","timestamp":1757738564000},"page":"1055-1070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03336333","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02242942","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0769","authenticated-orcid":false,"given":"Talha","family":"Munir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s","family":"Martinez-Calle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyun","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayad K.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyla","family":"Mohseninejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bal\u00e1zs","family":"Dobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pal","family":"Rakonczai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhys","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wassim","family":"Aldairy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"issue":"25","key":"380_CR1","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et\u00a0al. IwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360.","journal-title":"Blood"},{"issue":"12","key":"380_CR2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","volume":"34","author":"JA Burger","year":"2013","unstructured":"Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34(12):592\u2013601.","journal-title":"Trends Immunol"},{"issue":"1","key":"380_CR3","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2012.067","volume":"4","author":"DG Efremov","year":"2012","unstructured":"Efremov DG, Wiestner A, Laurenti L. Novel agents and emerging strategies for targeting the B-cell receptor pathway in CLL. Mediterr J Hematol Infect Dis. 2012;4(1):e2012067.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"380_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112011","author":"A Fresa","year":"2024","unstructured":"Fresa A, Innocenti I, Tomasso A, Stirparo L, Mosca A, Iadevaia F, et\u00a0al. Treatment sequencing in chronic lymphocytic leukemia in 2024: where we are and where we are headed. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16112011.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"380_CR5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","volume":"120","author":"JA Woyach","year":"2012","unstructured":"Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175\u201384.","journal-title":"Blood"},{"issue":"9","key":"380_CR6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","volume":"35","author":"B Eichhorst","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU, Kater AP, Gregor M, Hallek M, et\u00a0al. ESMO clinical practice guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35(9):762\u20138.","journal-title":"Ann Oncol"},{"issue":"11","key":"380_CR7","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et\u00a0al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440\u201350.","journal-title":"Blood Adv"},{"issue":"12","key":"380_CR8","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Barrientos JC, Barr PM, Reddy NM, et\u00a0al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353\u201363.","journal-title":"Am J Hematol"},{"issue":"6","key":"380_CR9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et\u00a0al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768\u201378.","journal-title":"Lancet Oncol"},{"key":"380_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/01.HS9.0000843476.36877.79","volume":"6","author":"S Stilgenbauer","year":"2022","unstructured":"Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, et\u00a0al. S146: venetoclax in patients with chronic lymphocytic leukemia with 17p deletion: 6-year follow-up and genomic analyses in a pivotal phase 2 trial. HemaSphere. 2022;6:47\u20138.","journal-title":"HemaSphere"},{"key":"380_CR11","unstructured":"AstraZeneca. Fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting. [cited 17 June 2025]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/fixed-duration-calquence-approved-in-eu-for-1l-cll.html."},{"key":"380_CR12","unstructured":"AbbVie Inc. Venclexta 2024 June 29, 2025. Available from: https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf."},{"key":"380_CR13","unstructured":"BeOne Medicines USA Inc. Brukinsa [Internet]. 2025 [cited 29 June 2025]. Available from: https:\/\/d1e94vsyskgtht.cloudfront.net\/brukinsa\/pdfs\/brukinsa-prescribing-information.pdf."},{"key":"380_CR14","unstructured":"Janssen Biotech Inc. Imbruvica 2024 June 29, 2025. Available from: https:\/\/www.rxabbvie.com\/pdf\/imbruvica_pi.pdf."},{"issue":"17","key":"380_CR15","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","volume":"62","author":"Y Guo","year":"2019","unstructured":"Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, et\u00a0al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2019;62(17):7923\u201340.","journal-title":"J Med Chem"},{"issue":"5","key":"380_CR16","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/JCO.22.00510","volume":"41","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Eichhorst B, Brown JR, Lamanna N, O\u2019Brien SM, Tam CS, et\u00a0al. Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2023;41(5):1035\u201345.","journal-title":"J Clin Oncol"},{"issue":"11","key":"380_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, et\u00a0al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851\u20139.","journal-title":"Blood"},{"issue":"8","key":"380_CR18","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, et\u00a0al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031\u201343.","journal-title":"Lancet Oncol"},{"issue":"7","key":"380_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO-24-02265","volume":"43","author":"M Shadman","year":"2025","unstructured":"Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, et\u00a0al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA. J Clin Oncol. 2025;43(7):780\u20137.","journal-title":"J Clin Oncol"},{"issue":"23","key":"380_CR20","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et\u00a0al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225\u201336.","journal-title":"N Engl J Med"},{"issue":"18","key":"380_CR21","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1182\/blood.2024024631","volume":"144","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, et\u00a0al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024;144(18):1924\u201335.","journal-title":"Blood"},{"issue":"6","key":"380_CR22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et\u00a0al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"issue":"6","key":"380_CR23","first-page":"1866","volume":"109","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Jen MH, Hess LM, Zhang J, Goebel B, Pagel JM, et\u00a0al. Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Haematologica. 2024;109(6):1866\u201373.","journal-title":"Haematologica"},{"issue":"4","key":"380_CR24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s10637-023-01376-1","volume":"41","author":"Y Song","year":"2023","unstructured":"Song Y, Zhou K, Yang S, Hu J, Zou D, Gao S, et\u00a0al. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma. Invest New Drugs. 2023;41(4):606\u201316.","journal-title":"Invest New Drugs"},{"issue":"9","key":"380_CR25","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"21","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et\u00a0al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188\u2013200.","journal-title":"Lancet Oncol"},{"issue":"1","key":"380_CR26","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","volume":"14","author":"O Al-Sawaf","year":"2023","unstructured":"Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, et\u00a0al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023;14(1):2147.","journal-title":"Nat Commun"},{"issue":"2","key":"380_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"key":"380_CR28","doi-asserted-by":"crossref","unstructured":"Shadman M, Brown JR, Williams R, Mohseninejad L, Yang K, Rakonczai P, et\u00a0al. Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R\/R CLL): a matching-adjusted indirect comparison (MAIC). In: 28th International Congress on Hematologic Malignancies; February 29\u2013March 3, 2024; Miami, FL2024.","DOI":"10.1177\/17588359251340554"},{"issue":"10","key":"380_CR29","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1080\/10428194.2021.1913144","volume":"62","author":"MS Davids","year":"2021","unstructured":"Davids MS, Telford C, Abhyankar S, Waweru C, Ringshausen I. Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naive chronic lymphocytic leukemia. Leuk Lymphoma. 2021;62(10):2342\u201351.","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"380_CR30","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et\u00a0al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337.","journal-title":"N Engl J Med"},{"issue":"9","key":"380_CR31","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","volume":"103","author":"PM Barr","year":"2018","unstructured":"Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, et\u00a0al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103(9):1502\u201310.","journal-title":"Haematologica"},{"issue":"1","key":"380_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","volume":"20","author":"C Moreno","year":"2019","unstructured":"Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et\u00a0al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43\u201356.","journal-title":"Lancet Oncol"},{"issue":"26","key":"380_CR33","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et\u00a0al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517\u201328.","journal-title":"N Engl J Med"},{"issue":"12","key":"380_CR34","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et\u00a0al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med"},{"issue":"2","key":"380_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/jnci\/djae245","volume":"117","author":"T Wen","year":"2025","unstructured":"Wen T, Sun G, Jiang W, Steiner K, Bridge S, Liu P. Comparing the efficacy and safety of first-line treatments for chronic lymphocytic leukemia: a network meta-analysis. J Natl Cancer Inst. 2025;117(2):322\u201334.","journal-title":"J Natl Cancer Inst"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00380-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00380-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00380-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:16:54Z","timestamp":1764087414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00380-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["380"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00380-0","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"type":"print","value":"2366-1070"},{"type":"electronic","value":"2366-1089"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Talha Munir\u2014honoraria: BeOne Medicines Ltd., AstraZeneca, Sobi, Roche, Janssen, AbbVie, and Lilly; consultant: AbbVie, BeOne Medicines Ltd., Sobi, Alexion, Novartis, Janssen, AstraZeneca, Lilly, and Roche; research grants: Janssen and AbbVie; travel, accommodations, or expenses: Alexion, BeOne Medicines Ltd., AbbVie, Janssen, and AstraZeneca; and advisory board: AbbVie, BeOne Medicines Ltd., AstraZeneca, and Janssen. Nicol\u00e1s Martinez-Calle\u2014advisory board: AbbVie, AstraZeneca, BeOne Medicines Ltd., Takeda, and CLS Behring; and speaker and honoraria: AbbVie, AstraZeneca, Janssen, and BeOne Medicines Ltd. Sheng Xu, Keri Yang, Xiaoyun Ge, Ayad K. Ali, Leyla Mohseninejad, Han Ma, Rhys Williams, and Wassim Aldairy\u2014employment and may own stock: BeOne Medicines Ltd. Bal\u00e1zs Dobi\u2014research funding: BeOne Medicines Ltd. Pal Rakonczai\u2014current affiliation: AstraZeneca; has nothing to disclose. Nicole Lamanna\u2014consulting or advisory role: AbbVie, AstraZeneca, BeOne Medicines Ltd., Lilly, and Genmab; and research funding: AbbVie, AstraZeneca, BeOne Medicines Ltd., Lilly, Genmab, Genentech, MingSight, Octapharma, and Oncternal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}